Elo Mutual Pension Insurance Co Sells 230 Shares of Catalent, Inc. (NYSE:CTLT)

Elo Mutual Pension Insurance Co cut its stake in shares of Catalent, Inc. (NYSE:CTLT) by 1.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,276 shares of the company’s stock after selling 230 shares during the period. Elo Mutual Pension Insurance Co’s holdings in Catalent were worth $915,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Lindbrook Capital LLC raised its position in shares of Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after acquiring an additional 208 shares during the period. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Catalent in the second quarter worth $42,000. Mather Group LLC. bought a new position in shares of Catalent during the first quarter worth $52,000. Longfellow Investment Management Co. LLC grew its holdings in shares of Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after buying an additional 305 shares during the period. Finally, Principal Securities Inc. bought a new stake in shares of Catalent in the 4th quarter valued at $56,000.

Catalent Stock Performance

Shares of CTLT opened at $60.00 on Friday. The stock has a market capitalization of $10.86 billion, a price-to-earnings ratio of -9.84, a PEG ratio of 1.88 and a beta of 1.15. Catalent, Inc. has a 12 month low of $31.80 and a 12 month high of $61.20. The firm has a fifty day simple moving average of $59.48 and a 200 day simple moving average of $57.21. The company has a current ratio of 2.52, a quick ratio of 1.77 and a debt-to-equity ratio of 1.35.

Insider Transactions at Catalent

In related news, SVP Scott Gunther sold 666 shares of the company’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $59.55, for a total transaction of $39,660.30. Following the sale, the senior vice president now owns 39,635 shares in the company, valued at $2,360,264.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Catalent news, SVP Scott Gunther sold 666 shares of the company’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the sale, the senior vice president now directly owns 39,635 shares of the company’s stock, valued at $2,360,264.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ricky Hopson sold 662 shares of Catalent stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the completion of the transaction, the insider now directly owns 29,974 shares of the company’s stock, valued at approximately $1,785,251.44. The disclosure for this sale can be found here. Insiders sold a total of 13,409 shares of company stock worth $782,923 in the last three months. Insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

CTLT has been the subject of a number of research analyst reports. StockNews.com began coverage on Catalent in a research note on Wednesday. They issued a “sell” rating for the company. William Blair restated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Barclays upped their price target on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a report on Friday, June 28th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research report on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat, Catalent has an average rating of “Hold” and an average price target of $58.08.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.